BRPI0411563B8 - uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida - Google Patents
uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamidaInfo
- Publication number
- BRPI0411563B8 BRPI0411563B8 BRPI0411563A BRPI0411563A BRPI0411563B8 BR PI0411563 B8 BRPI0411563 B8 BR PI0411563B8 BR PI0411563 A BRPI0411563 A BR PI0411563A BR PI0411563 A BRPI0411563 A BR PI0411563A BR PI0411563 B8 BRPI0411563 B8 BR PI0411563B8
- Authority
- BR
- Brazil
- Prior art keywords
- nmethylbenzamide
- benzodiazonin
- pyrrolo
- hexahydro
- indole
- Prior art date
Links
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 206010013700 Drug hypersensitivity Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005311 drug allergy Diseases 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 208000008585 mastocytosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
uso para derivados de estaurosporina. a presente invenção refere-se ao uso dos derivados de estaurosporinas para tratamento curativo, paliativo ou profilático de rinite alérgica, dermatite alérgica, alergia aos fármacos ou alergia aos alimentos, angioedema, urticária, síndrome de morte súbita infantil, aspergilose broncopulmonar, esclerose múltipla ou mastocitose; e a um processo para tratamento de animais de sangue quente, onde uma dose terapeuticamente de um composto de um derivado de estaurosporina é administrada a um animal de sangue quente que sofre de uma das doenças ou condições mencionadas acima.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47957503P | 2003-06-18 | 2003-06-18 | |
US60/479,575 | 2003-06-18 | ||
PCT/EP2004/006562 WO2004112794A2 (en) | 2003-06-18 | 2004-06-17 | New pharmaceutical uses of staurosporine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0411563A BRPI0411563A (pt) | 2006-08-01 |
BRPI0411563B1 BRPI0411563B1 (pt) | 2019-09-24 |
BRPI0411563B8 true BRPI0411563B8 (pt) | 2021-05-25 |
Family
ID=33539193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411563A BRPI0411563B8 (pt) | 2003-06-18 | 2004-06-17 | uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida |
Country Status (24)
Country | Link |
---|---|
US (2) | US8575146B2 (pt) |
EP (1) | EP1638574B1 (pt) |
JP (2) | JP5057780B2 (pt) |
CN (2) | CN101164539A (pt) |
AT (1) | ATE464052T1 (pt) |
AU (1) | AU2004248909B2 (pt) |
BE (1) | BE2017C067I2 (pt) |
BR (1) | BRPI0411563B8 (pt) |
CA (2) | CA2785950A1 (pt) |
CY (2) | CY1110179T1 (pt) |
DE (1) | DE602004026578D1 (pt) |
DK (1) | DK1638574T3 (pt) |
ES (1) | ES2344700T3 (pt) |
FR (1) | FR17C1063I2 (pt) |
HK (1) | HK1095519A1 (pt) |
HU (1) | HUS000503I2 (pt) |
LU (1) | LUC00055I9 (pt) |
MX (1) | MXPA05013722A (pt) |
NL (1) | NL300917I2 (pt) |
PL (1) | PL1638574T3 (pt) |
PT (1) | PT1638574E (pt) |
SI (1) | SI1638574T1 (pt) |
TW (1) | TWI324604B (pt) |
WO (1) | WO2004112794A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
CN1882344A (zh) | 2003-11-18 | 2006-12-20 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
CN103251953A (zh) * | 2004-07-19 | 2013-08-21 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
JP5129123B2 (ja) * | 2005-05-02 | 2013-01-23 | ノバルティス アーゲー | 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用 |
DE602006013826D1 (de) * | 2005-07-20 | 2010-06-02 | Peter Valent | Zusammensetzungen zur behandlung von systemischer mastocytose |
EP1951255A1 (en) * | 2005-11-14 | 2008-08-06 | Universität Zürich | Staurosporine derivatives for use in alveolar rhabdomyosarcoma |
WO2009092442A1 (en) * | 2008-01-23 | 2009-07-30 | Universidad De Barcelona | Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways |
US8802099B2 (en) * | 2010-11-10 | 2014-08-12 | National Jewish Health | Methods to treat allergic conditions |
CR20210287A (es) | 2018-11-01 | 2022-02-15 | Syros Pharmaceuticals Inc | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) |
WO2020097261A1 (en) * | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639455A (en) * | 1984-10-02 | 1987-01-27 | Key Pharmaceuticals, Inc. | Means of aiding in the prevention of sudden infant death syndrome |
JPH0826037B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
DK0518468T3 (da) * | 1991-05-09 | 2000-01-31 | Neurim Pharma 1991 | Melatoninholdige sammensætninger |
AR004480A1 (es) | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
NZ333441A (en) * | 1996-06-25 | 1999-05-28 | Cephalon Inc | Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
DE60112611T2 (de) * | 2000-12-08 | 2006-06-14 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
EP1471907B1 (en) * | 2001-06-29 | 2008-07-16 | AB Science | Use of c-kit inhibitors for treating autoimmune diseases |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
CN1582150B (zh) | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
EP1645286A1 (en) * | 2003-04-18 | 2006-04-12 | Kyowa Hakko Kogyo Co., Ltd. | Drug for nerve regeneration |
JPWO2004093910A1 (ja) * | 2003-04-22 | 2006-07-13 | アステラス製薬株式会社 | PPARδアゴニストによる脳神経変性疾患治療剤 |
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
CN1882344A (zh) | 2003-11-18 | 2006-12-20 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
-
2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en active Active
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 EP EP04740016A patent/EP1638574B1/en active Active
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de active Active
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja active Active
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es active Active
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh active Active
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 CA CA2527703A patent/CA2527703C/en active Active
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
-
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx unknown
-
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
-
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
-
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
-
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411563B8 (pt) | uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida | |
DK1611088T3 (da) | Hydroxymater som terapeutiske midler | |
NO20061253L (no) | Acetylenderivater som inhibitorer av histon deacetylase | |
BRPI0213739B8 (pt) | derivados de estaurosporina como inibidores da atividade de receptores flt3 de tirosina cinase | |
CA2564684C (en) | Use of thioxanthene derivatives as chemosensitising compounds | |
EP1592665A4 (en) | HISTONE DEACETYLASE INHIBITORS OF NEW POWERFUL DIFFERENTIATION BENZAMIDE DERIVATIVES WITH PROLIFERATION-INHIBITING ACTIVITY | |
BR0311931A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente | |
BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
BRPI0517084A (pt) | composto de éster, composição farmacêutica, inibidor da proteìna de transferência de triglicerìdeo microssÈmico, agente de diminuição de pelo menos um dos parámetros lipìdicos do sangue, método para o tratamento ou profilaxia de uma doença, embalagem comercial, e, uso do composto de éster | |
PT1231915E (pt) | Uso de derivados de pleuromutilina para tratamento transdermal de doencas bacterianas | |
BR0313503A (pt) | Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna | |
BR0315374A (pt) | Compostos orgânicos | |
BRPI0414564A (pt) | derivados de 2-alcilideno-19-nor-vitamina d para tratamento de fraqueza, lesão muscular ou sarcopenia | |
CO4290357A1 (es) | Derivados de la cefalosporina, preparaciones farmaceuticas que las contienen y procedimiento para su preparacion y em- pleo. | |
BR0209578A (pt) | Uso de um gatran ou de um derivado farmaceuticamente aceitável do mesmo, método de tratamento de fibrose pulmonar, e, formulação farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09T | Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |